Millions take them for rapid weight loss and diabetes management. Now, the prescription boxes will carry a sobering caution. The Food and Drug Administration ruled on Monday that popular GLP-1 medications—including Ozempic, Wegovy, Mounjaro, and Zepbound—must display updated packaging warnings about a rare eye condition capable of triggering permanent vision loss. Regulators confirmed the safety update covers the entire class of GLP-1 drugs, spanning roughly a dozen injectables and oral tablets.
FDA scientists traced the hazard to non-arteritic anterior ischemic optic neuropathy, a condition commonly known as NAION. The disorder strikes when blood supply to the optic nerve abruptly drops, starving sensitive eye tissue of oxygen. Federal regulators cautioned that while the link between reduced blood flow and the drugs is established, the exact biological trigger remains unclear. The agency launched its comprehensive safety review after a 2024 medical paper first connected NAION cases to patients using semaglutide.
To gauge the true magnitude of the danger, federal researchers combed through data spanning more than 125 clinical trials. The numbers show the risk is exceedingly small, yet distinct. About 6 out of every 100,000 patients who took a GLP-1 medication for at least one year developed the eye disorder. Among patients assigned a placebo or prescribed alternative blood-sugar drugs, the rate slipped below 4 per 100,000. Regulators corroborated those findings with independent adverse incident reports logged across federal drug surveillance databases.
Sight changes can emerge without warning. The agency instructed healthcare providers and patients to monitor for early visual red flags, including sudden blurriness, darkened patches in the field of vision, distorted colors, and partial blind spots. And speed matters. When blood flow drops to the optic nerve, delay risks irreversible harm. The FDA cautioned that anyone noticing visual disturbances while taking GLP-1 therapies must halt regular dosing assumptions and seek immediate medical evaluation.